Alamo Pharma Services and BexR Logistix Leaders to Participate in the Synergistix Solutions through Partnerships Conference Panel Discussions

SAN ANTONIO (March 7, 2017) – Peter Marchesini, Chief Operating Officer of Alamo Pharma Services, Inc. (“Alamo”), and Daniel J. Harmon, Jr., General Manager and Vice President of Business Development at BexR Logistix, LLC (“BexR”), will participate in the 13th annual Synergistix Solutions through Partnerships Conference in Pompano Beach, Florida, March 8-10, 2017. The conference is an invitation only event for pharmaceutical and life sciences executives, that focuses on key aspects of product commercialization and operations in the pharmaceutical and medical device arena.

Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for Mytesi™

SAN FRANCISCO, CA (February 28, 2017) — Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally used in rainforest areas, announces today that it has signed an agreement with Alamo Pharma Services, Inc. for the establishment and management of a national sales team for Mytesi™ (formerly known as Fulyzaq). Mytesi™, launched by Napo in October 2016, is approved by the U.S.

Mission Pharmacal Announces Continued Support of March of Dimes® and Signature Fundraiser, March for Babies®

SAN ANTONIO (February 9, 2017) – Mission Pharmacal Company (“Mission”) celebrated the kick off of its 2017 fundraising campaign in support of the March of Dimes Foundation®, and its signature fundraiser March for Babies. The March of Dimes is committed to a world in which every baby gets a fighting chance. The company has been a national supporter of the March of Dimes since 2010 and during that time has contributed more than $2.1 million dollars to the organization through corporate sponsorship and fundraising efforts.

Alamo Pharma Services Announces Launch of New Website

DOYLESTOWN, PA. (February 7, 2017) — Alamo Pharma Services, Inc. (“Alamo”), a leading pharmaceutical commercial solutions provider and member of the Mission Family of Companies, today announced the launch of their updated website AlamoPharmaServices.com.

Mission Pharmacal Invests In Elements of Genius In Advance of Upcoming “Wellnest” Launch

SAN ANTONIO (January 24, 2017) – Mission Pharmacal Company (“Mission”) today announced it has invested in the company Elements of Genius (“Elements”) and their flagship product Wellnest™. This investment comes as Elements prepares for the July 1, 2017, launch of Wellnest – a mobile device worn by seniors and designed to enhance the user’s health and wellness – further expanding Mission’s reach into the senior care market.

Mission Pharmacal Business Development Team Returns to J.P. Morgan Healthcare Conference

SAN ANTONIO (January 9, 2017) – Today marks the opening of the 35th annual J.P.

Mission Pharmacal Serves as Platinum Sponsor of March of Dimes Foundation “Nurse of the Year” Awards In New Jersey and Georgia

SAN ANTONIO (November 30, 2016) – Mission Pharmacal Company (Mission) served as Platinum Sponsor for two recent March of Dimes Foundation Annual Nurse of the Year (NOTY) Awards events. The first occurred on Wednesday, November 16, when March of Dimes (MOD) North Central

Incidence of Lice and Pesticide-Resistant “Super Lice” Rises in the U.S. As the Nation’s Youth Go Back to School

SAN ANTONIO (September 22, 2016) – As students across the United States revel in the excitement of the “back-to-school” season, anxious parents and school nurses are faced with the annual spike in cases of head lice that coincide with the return to class. Head lice are tiny, wingless insects that live on the human scalp and spread between people by head-to-head contact or the sharing of hats, combs, brushes, or towels. August and September are traditionally months with the highest lice infestation rates.

ProSolus, Inc. Chief Operating Officer Named to PharmaVOICE 100 Most Inspiring People

SAN ANTONIO (August 8, 2016) – Mission Pharmacal Company today announced that Juan Mantelle, Chief Operating Officer of its wholly-owned subsidiary ProSolus®, Inc., has been named to PharmaVOICE magazine’s prestigious annual list of the 100 most inspiring people in the life sciences. These elite recipients are moving the industry forward and improving all aspects of healthcare by imagining, creating, and executing new possibilities.

Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDerm®

SAN ANTONIO (July 26, 2016) – Espada Dermatology™, Inc. (Espada) announced today the recent purchase of the  GlyDerm® line of skin care products from Lautus Pharmaceuticals, LLC. Espada is a wholly-owned subsidiary of Mission Pharmacal Company (Mission) and adds breadth to Mission’s established line of dermatological drug products.